Monomethyl Fumarate
Adult Acute Myelomonocytic Leukemia (M4)
Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Adult Acute Myelomonocytic Leukemia (M4) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Stanford University | Phase 3 | BBB |
Cytosin-Arabinosid University of Alberta | Phase 3 | BBB |
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
Cyclophosphamide ECOG-ACRIN Cancer Research Group | Phase 3 | BBB |
Idarubicine University of Alberta | Phase 3 | BBB |
View all 49 →
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →